Physician profile
Terry Chin
NPI 1811093305
$320.32
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $200.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $74.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $53.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $36.96 | 2019-2020 | |
| Horizon Therapeutics Plc | $26.00 | 2020 | |
| Csl Behring | $24.82 | 2020 | |
| Allergan, INC. | $24.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.45 | 2020 | |
| Genzyme Corporation | $20.25 | 2020 | |
| Genentech USA, INC. | $18.80 | 2019 | |
| Pfizer INC. | $17.52 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Chin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.